Monograph: |
BLONANSERIN
Β· SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS
Β· DOPAMINE ANTAGONISTS
Β· SEROTONIN RECEPTOR ANTAGONISTS
ANTIDEPRESSANT
DESCRIPTION
BLONANSERIN IS AN ATYPICAL ANTIPSYCHOTIC APPROVED IN JAPAN IN JANUARY, 2008. IT OFFERS IMPROVED TOLERABILITY AS IT LACKS SIDE EFFECTS SUCH AS EXTRAPYRAMIDAL SYMPTOMS, EXCESSIVE SEDATION, OR HYPOTENSION. AS A SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTIC, IT IS SIGNIFICANTLY MORE EFFICACIOUS IN THE TREATMENT OF THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA COMPARED TO FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS.
PHARMACOLOGY
INDICATION
USED FOR THE TREATMENT OF SCHIZOPHRENIA .
PHARMACODYNAMICS
BLONANSERIN ANTAGONIZES DOPAMINE AND SEROTONIN RECEPTORS TO REDUCE SYMPTOMS OF SCHIZOPHRENIA .
MECHANISM OF ACTION
BLONANSERIN BINDS TO AND INHIBITS DOPAMINE RECEPTORS D2 AND D3 AS WELL AS THE SEROTONIN RECEPTOR 5-HT2A WITH HIGH AFFINITY . BLONANSERIN HAS LOW AFFINITY FOR OTHER DOPAMINE AND SEROTONIN RECEPTORS AS WELL AS MUSCARINIC, ADRENERGIC, AND HISTAMINE RECEPTORS. THIS REDUCES DOPAMINERGIC AND SEROTONERGIC NEUROTRANSMISSION WHICH IS THOUGHT TO PRODUCE A REDUCTION IN POSITIVE AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA RESPECTIVELY.
METABOLISM
BLONANSERIN IS MAINLY METABOLIZED BY CYP3A4 . IT UNDERGOES HYDOXYLATION OF THE CYCLOOCTANE RING AS WELL AS N-OXIDATION AND N-DEETHYLATION OF THE PIPERAZINE RING. THE N-DEETHYLATED AND HYDROXYLATED METABOLITES ARE ACTIVE BUT TO A LESSER DEGREE THAN THE PARENT DRUG.
THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH (R)-WARFARIN.
(S)-WARFARIN THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH (S)-WARFARIN.
2,5-DIMETHOXY-4-ETHYLAMPHETAMINE THE RISK OR SEVERITY OF SEROTONIN SYNDROME CAN BE INCREASED WHEN 2,5-DIMETHOXY-4-ETHYLAMPHETAMINE IS COMBINED WITH BLONANSERIN.
2,5-DIMETHOXY-4-ETHYLTHIOAMPHETAMINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH 2,5-DIMETHOXY-4-ETHYLTHIOAMPHETAMINE.
3,5-DINITROCATECHOL THE THERAPEUTIC EFFICACY OF 3,5-DINITROCATECHOL CAN BE DECREASED WHEN USED IN COMBINATION WITH BLONANSERIN.
4-BROMO-2,5-DIMETHOXYAMPHETAMINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN 4-BROMO-2,5-DIMETHOXYAMPHETAMINE IS COMBINED WITH BLONANSERIN.
4-HYDROXYCOUMARIN THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH 4-HYDROXYCOUMARIN.
4-METHOXYAMPHETAMINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN 4-METHOXYAMPHETAMINE IS COMBINED WITH BLONANSERIN.
5-METHOXY-N,N-DIMETHYLTRYPTAMINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH 5-METHOXY-N,N-DIMETHYLTRYPTAMINE.
7-NITROINDAZOLE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN 7-NITROINDAZOLE IS COMBINED WITH BLONANSERIN.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE IS COMBINED WITH BLONANSERIN.
ABACAVIR ABACAVIR MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ACARBOSE ACARBOSE MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ACECLOFENAC ACECLOFENAC MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ACEMETACIN ACEMETACIN MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ACENOCOUMAROL THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH ACENOCOUMAROL.
ACEPROMAZINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ACEPROMAZINE IS COMBINED WITH BLONANSERIN.
ACEPROMETAZINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ACEPROMETAZINE IS COMBINED WITH BLONANSERIN.
ACETAMINOPHEN ACETAMINOPHEN MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ACETAZOLAMIDE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ACETAZOLAMIDE IS COMBINED WITH BLONANSERIN.
ACETOPHENAZINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ACETOPHENAZINE IS COMBINED WITH BLONANSERIN.
ACETYLGLYCINAMIDE CHLORAL HYDRATE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH ACETYLGLYCINAMIDE CHLORAL HYDRATE.
ACETYLSALICYLIC ACID ACETYLSALICYLIC ACID MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ACLIDINIUM BLONANSERIN MAY INCREASE THE CENTRAL NERVOUS SYSTEM DEPRESSANT (CNS DEPRESSANT) ACTIVITIES OF ACLIDINIUM.
ACRIVASTINE BLONANSERIN MAY DECREASE THE EXCRETION RATE OF ACRIVASTINE WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ACYCLOVIR ACYCLOVIR MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ADEFOVIR ADEFOVIR MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ADEFOVIR DIPIVOXIL ADEFOVIR DIPIVOXIL MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ADINAZOLAM THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ADINAZOLAM IS COMBINED WITH BLONANSERIN.
ADIPIPLON THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ADIPIPLON IS COMBINED WITH BLONANSERIN.
AGOMELATINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AGOMELATINE IS COMBINED WITH BLONANSERIN.
AJULEMIC ACID THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN AJULEMIC ACID IS COMBINED WITH BLONANSERIN.
ALAPROCLATE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH ALAPROCLATE.
ALBUTREPENONACOG ALFA BLONANSERIN MAY DECREASE THE EXCRETION RATE OF ALBUTREPENONACOG ALFA WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ALCLOFENAC ALCLOFENAC MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ALCURONIUM THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH ALCURONIUM.
ALDESLEUKIN ALDESLEUKIN MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ALFAXALONE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH ALFAXALONE.
ALFENTANIL THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALFENTANIL IS COMBINED WITH BLONANSERIN.
ALIMEMAZINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALIMEMAZINE IS COMBINED WITH BLONANSERIN.
ALLOBARBITAL THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH ALLOBARBITAL.
ALLOPURINOL ALLOPURINOL MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ALLYLESTRENOL ALLYLESTRENOL MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ALMASILATE BLONANSERIN MAY DECREASE THE EXCRETION RATE OF ALMASILATE WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ALMINOPROFEN ALMINOPROFEN MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ALMOTRIPTAN THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALMOTRIPTAN IS COMBINED WITH BLONANSERIN.
ALOGLIPTIN ALOGLIPTIN MAY DECREASE THE EXCRETION RATE OF BLONANSERIN WHICH COULD RESULT IN A HIGHER SERUM LEVEL.
ALOSETRON THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALOSETRON IS COMBINED WITH BLONANSERIN.
ALPHACETYLMETHADOL THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN ALPHACETYLMETHADOL IS COMBINED WITH BLONANSERIN.
ALPHAPRODINE THE RISK OR SEVERITY OF ADVERSE EFFECTS CAN BE INCREASED WHEN BLONANSERIN IS COMBINED WITH ALPHAPRODINE.
|